United Therapeutics (UTHR) EBITDA (2009 - 2026)

United Therapeutics has disclosed EBITDA across 18 years of filings, most recently posting $325.8 million for Q1 2026.

• EBITDA for Q1 2026 came in at $325.8 million, down 14.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 2.28% YoY), and the FY2025 annual result was $1.5 billion, up 8.39% from the prior year.
• EBITDA came in at $325.8 million for Q1 2026 at United Therapeutics, down from $356.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $388.5 million in Q3 2025 to a low of $175.6 million in Q4 2022.
• The 5-year median for EBITDA is $325.8 million (2026), against an average of $315.3 million.
• Across the five-year window, EBITDA jumped 544.44% in 2022 and slipped 14.89% in 2026, its largest moves.
• United Therapeutics' EBITDA stood at $175.6 million in 2022, then soared by 48.12% to $260.1 million in 2023, then jumped by 37.52% to $357.7 million in 2024, then slipped by 0.28% to $356.7 million in 2025, then slipped by 8.66% to $325.8 million in 2026.
• The last three EBITDA figures came in at $325.8 million (Q1 2026), $356.7 million (Q4 2025), and $388.5 million (Q3 2025), per Business Quant data.